A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone Across All Treatment Lines in Patients with MSI-high or dMMR mCRC By Ogkologos - February 5, 2025 655 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma Mortality Trends for Most Cancers Remain Favourable In the EU, Although the Absolute Number of Cancer Deaths Is Not Declining Due To Population Ageing MOST POPULAR Long-Term Clinical Benefit with Nivolumab Plus Ipilimumab Extends Beyond Treatment Discontinuation... October 18, 2022 Is there a right way to check your body for cancer? March 29, 2022 3 Questions Cancer Caregivers Can Ask Themselves to Help Prevent Burnout July 29, 2021 The Investigational PD1 Antibody, Tislelizumab, Shows Promise in Patients With Unresectable... July 1, 2021 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Dostarlimab Female Breast Cancer is Now the Most Commonly Diagnosed Cancer in... 25-Year-Old Mom Had Chemo & Surgery, Then Was Told She Never... Doctors Think Woman Has A Brain Tumor, But Then They Open...
